CD69 and atrial fibrillation: Additionally, concentrated AF-EVs reduced T cell activation significantly more than acAF treatment in CD25+ (p<0.0001), CD69+ (p<0.001), and CD25+CD69+ (p<0.001) cells (Figure 4B).